Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Review does not support use of ACEIs in dogs with preclinical MMVD
The study found that administration of ACEIs to dogs with preclinical MMVD and cardiomegaly results in little or no difference in the risk of developing congestive heart failure

Researchers review adverse events of angiotensin-converting enzyme inhibitor use.

The use of angiotensin-converting enzyme inhibitors (ACEIs) for managing preclinical myxomatous mitral valve disease (MMVD) in dogs results in little or no difference in the risk of developing conegestive heart failure, according to new research.

The study, published in the Journal of Small Animal Practice, is the first comprehensive systematic review and meta-analysis on the efficacy and adverse events of ACEIs for the condition, often seen in cavalier King Charles spaniels and dachshunds.

It found that administration of ACEIs to dogs with preclinical MMVD and cardiomegaly results in little or no difference in the risk of developing congestive heart failure and may result in little or no difference in cardiovascular-related and all-cause mortality. 

The study was conducted by researchers in Argentina, Italy, Austria and Chile, who set out to evaluate the efficacy of and adverse events from the administration of ACEIs, via a systematic review of published evidence conducted according to the Cochrane Handbook for Systematic Reviews of Interventions.

Certainty of evidence was assessed using the GRADE approach, and the main finding in relation to dogs with preclinical MMVD and cardiomegaly backed by a high certainty of evidence. The certainty of evidence relating to the efficacy of ACEI administration in dogs without cardiomegaly was low.

Dr Pablo Donati, corresponding author for the paper, commented: “In recent times, multiple clinical trials have provided fundamental information to veterinary cardiology. In the era of evidence-based medicine, systematic reviews and meta-analyses have emerged as a fundamental tool for clinical decision-making by gathering, appraising and summarizing the best available evidence. 

"It is the hope of the authors that this systematic review and meta-analysis helps in the decision-making process for the treatment of preclinical myxomatous mitral disease with angiotensin-converting enzyme inhibitors in dogs.” 

Nicola Di Girolamo, Editor of JSAP, added: “In line with other leading journals, the JSAP is prioritizing the publication of methodologically sound systematic reviews such as this one. However, our readers should be aware that the findings of systematic reviews should always be considered in light of their internal validity, i.e. the quality of the included studies, and their external validity, i.e. the generalizability of the included studied to the individual patient.”

Image (C) Dr Pablo Donati.

 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
RCVS Regional Question Time heads to Edinburgh

The RCVS is to bring its Regional Question Time (RQT) to Edinburgh for 2026.

The event will take place at Novotel Edinburgh Park in Edinburgh on Wednesday, 20 May 2026.

It will begin with supper and drinks at 6.30pm, with an evening programme from 7.30pm. This will start with an update on RCVS' activities, followed by questions and answers with representatives.

RCVS is encouraging an 'open dialogue', in which queries can be raised in a friendly, informal environment.

While discussions are expected to be audience-led, the RQT is expected address major issues including the VSA, the CMA's remedy package and the VN Vision project.

Tim Parkin, RCVS president, said: "It's an important time for the professions, and I'm looking forward to meeting colleagues in Scotland as we navigate this period of change together so we can come out stronger."

Tickets can be booked here.